Inflammation and skin cholesterol in LDLr 2 / 2 , apoA-I 2 / 2 mice : link between cholesterol homeostasis and self-tolerance ?
Manal Zabalawi,M. Bharadwaj,Heather Horton,M. Cline,M. Willingham,Michael J. Thomas,M. Sorci-Thomas
Abstract:Diet-fed low density lipoprotein receptor-deficient/apolipoprotein A-I-deficient (LDLr, apoA-I) mice accumulate a 10-fold greater mass of cholesterol in their skin despite a 1.5to 2-fold lower plasma cholesterol concentration compared with diet-fed LDLr mice. The accumulation of cholesterol predominantly in the skin has been shown to occur in a growing number of other hypercholesterolemic double knockout mouse models sharing deficits in genes regulating cellular cholesterol homeostasis. Exploring the relationship between cholesterol balance and inflammation, we have examined the time course of cholesterol accumulation in a number of extrahepatic tissues and correlated with the onset of inflammation in diet-fed LDLr, apoA-I mice. After 4 weeks of diet, LDLr, apoA-I mice showed a significant increase in skin cholesterol mass compared with LDLr mice. In addition, after 4 weeks on the diet, cholesterol accumulation in the skin was also found to be associated with macrophage infiltration and accompanied by increases in tumor necrosis factor-a, cyclooxygenase-2, and langerin mRNA, which were not seen in the liver. Overall, these data suggest that as early as 4 weeks after starting the diet, the accumulation of skin cholesterol and the onset of inflammation occur concurrently. In summary, the use of hypercholesterolemic LDLr, apoA-I mice may provide a useful tool to investigate the role that apoA-I plays in maintaining cholesterol homeostasis and its relationship to inflammation.—Zabalawi, M., M. Bharadwaj, H. Horton, M. Cline,M.Willingham,M. J. Thomas, andM.G. Sorci-Thomas. Inflammation and skin cholesterol in LDLr, apoA-I mice: link between cholesterol homeostasis and self-tolerance? J. Lipid Res. 2007. 48: 52–65. Supplementary key words apolipoprotein A-I & high density lipoprotein & inflammation & low density lipoprotein receptor-deficient/ apolipoprotein A-I-deficient mice & whole body cholesterol & skin & itch The plasma HDL apolipoprotein A-I (apoA-I) concentration is a powerful inverse correlate of atherosclerosis risk in humans (1). The most prominent mechanism explaining its atheroprotective role is through the directional movement of peripheral tissue cholesterol to the liver via a pathway referred to as “reverse cholesterol transport.” This pathway describes a mechanism of cholesterol removal and was first proposed by Glomset and Norum (2). Excess cholesterol is removed from peripheral tissues and cells organized by apoA-I into phospholipid complexes, then transported to the liver for excretion. A number of steps have been shown to be critical in completing the overall pathway (3). In vivo studies aimed at establishing the role of HDL apoA-I as the main physiological efflux acceptor of peripheral tissue cholesterol have shown that the absence of apoA-I has little or no effect on centripetal cholesterol transport, suggesting that the movement of peripheral tissue cholesterol via HDL apoA-I is not a rate-limiting step in net cholesterol removal (4–7). In other studies, the role of apoA-I in reverse cholesterol transport has been tested with specific emphasis on macrophage cholesterol and not peripheral tissue cholesterol efflux. In one report (8), apoA-I was found to inhibit foam cell formation in apoE knockout mice after monocyte adherence to endothelium. In another study, mice deficient in both apoE and apoA-I but expressing macrophage-derived apoE were found to have 2to 3-fold lower plasma cholesterol than mice deficient in only apoE and expressing macrophage apoE. In spite of the lower plasma cholesterol, the apoA-I and apoE double knockout mice had atherosclerotic lesions 60% larger than in the apoE only knockout mice expressing macrophage apoE (9). More recently, using a method of monitoring the in vivo fate of radiolabeled macrophage cholesterol, a study showed that overexpression of liver-derived apoA-I promotes reverse cholesterol transport from macrophages to feces more efficiently than in mice with normal levels of plasma apoA-I (10). Using the same method, liverManuscript received 17 August 2006 and in revised form 12 October 2006. Published, JLR Papers in Press, October 28, 2006. DOI 10.1194/jlr.M600370-JLR200 To whom correspondence should be addressed. e-mail: msthomas@wfubmc.edu Copyright D 2007 by the American Society for Biochemistry and Molecular Biology, Inc. This article is available online at http://www.jlr.org 52 Journal of Lipid Research Volume 48, 2007 by gest, on A uust 7, 2017 w w w .j.org D ow nladed fom 0.DC1.html http://www.jlr.org/content/suppl/2006/10/31/M600370-JLR20 Supplemental Material can be found at: